NLS Pharmaceutics AG (NLSP) — Cash Flow-to-Debt Ratio
NLS Pharmaceutics AG (NLSP) has a Cash Flow-to-Debt Ratio of -1.43x as of September 2025, meaning its operating cash flow of $-2.07 Million could theoretically repay -1% of its total liabilities ($1.46 Million) in one year. See NLS Pharmaceutics AG free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NLS Pharmaceutics AG Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for NLS Pharmaceutics AG across 8 annual periods. Also explore NLSP year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for NLS Pharmaceutics AG (2017–2024)
Year-by-year debt coverage analysis for NLS Pharmaceutics AG. For market capitalisation and broader financial context, see NLS Pharmaceutics AG stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -5.16x | $-4.27 Million | $826.76K | ▼ -469.3% |
| 2023 | -0.91x | $-9.68 Million | $10.68 Million | ▲ +60.8% |
| 2022 | -2.31x | $-13.88 Million | $6.00 Million | ▲ +19.1% |
| 2021 | -2.86x | $-14.94 Million | $5.22 Million | ▼ -3897.9% |
| 2020 | -0.07x | $-729.39K | $10.20 Million | ▼ -158.6% |
| 2019 | -0.03x | $-190.01K | $6.87 Million | ▲ +90.9% |
| 2018 | -0.31x | $-2.73 Million | $8.96 Million | ▲ +43.8% |
| 2017 | -0.54x | $-5.43 Million | $10.01 Million | — |